A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn*s Disease

Inclusion Criteria
Each patient must meet all of the following inclusion criteria to be enrolled in the study:
1. Age 18 to 80
2. Male or female patient who is voluntarily able to give informed consent
3. Female patients who:
* Are post-menopausal for at least 1 year before the screening visit, OR
* Are surgically sterile, OR
* If they are of childbearing potential, agree to practice 2 effective methods of
contraception, at the same time, from four weeks before the first dose of
study drug through 6 months after the last dose of study drug, OR agree to
completely abstain from heterosexual intercourse.
Male patients, even if surgically sterilized (ie, status post-vasectomy), who:
* Agree to practice effective barrier contraception during the entire study
treatment period and through 6 months after the last dose of study drug, OR
* Agree to completely abstain from heterosexual intercourse.
4. Diagnosis of Crohn*s disease established at least 6 months prior to enrollment by
clinical and endoscopic evidence and corroborated by a histopathology report.
Cases of Crohn*s disease established at least 12 months prior to enrollment for
which a histopathology report is not available will be considered based on the
weight of the evidence supporting the diagnosis and excluding other potential
diagnoses, and must be discussed with the sponsor on a case-by-case basis prior to
enrollment.
5. Moderately to severely active Crohn*s disease as determined by a CDAI score of
220 to 480 (see Section 15.1) within 7 days prior to the first dose of study drug
and 1 of the following:
a. CRP level >2.87 mg/L during the screening period OR
b. Ileocolonoscopy with photographic documentation of a minimum of 3 nonanastomotic
ulcerations (each >0.5 cm in diameter; aphthous ulcerations are
not sufficient) consistent with CD within 4 months prior to screening
Millennium Pharmaceuticals, Inc. Clinical Study Protocol C13007
MLN0002 EudraCT Number: 2008-002783-33 26 June 2008
Confidential 41
6. CD involvement of the ileum and/or colon, at a minimum
7. Patients with extensive colitis or pancolitis of >8 years duration or left-sided
colitis of >12 years duration must have documented evidence that a surveillance
colonoscopy was performed within 12 months of the initial screening visit (may
be performed during screening).
8. Patients with a family history of colorectal cancer, personal history of increased
colorectal cancer risk, age >50 years, or other known risk factor must be up-todate
on colorectal cancer surveillance (may be performed during screening)
9. Demonstrated, over the previous 5 year period, an inadequate response to, loss of
response to, or intolerance of at least one of the following agents as defined
below:
* Corticosteroids
o Signs and symptoms of persistently active disease despite a history of at
least one 4-week induction regimen that included a dose equivalent to
prednisone 30 mg daily orally for 2 weeks or intravenously for 1 week OR
o Two failed attempts to taper corticosteroids to below a dose equivalent to
prednisone 10 mg daily orally on two separate occasions OR
o History of intolerance of corticosteroids (including, but not limited to
Cushing*s syndrome, osteopenia/osteoporosis, hyperglycemia, insomnia,
infection)
* Immunomodulators
o Signs and symptoms of persistently active disease despite a history of at
least one 8 week regimen of oral azathioprine (*1.5 mg/kg) or 6-
mercaptopurine mg/kg (*0.75 mg/kg) OR
o Signs and symptoms of persistently active disease despite a history of at
least one 8 week regimen of methotrexate (*12.5 mg/week) OR
o History of intolerance of at least one immunomodulator (including, but not
limited to nausea/vomiting, abdominal pain, pancreatitis, LFT
abnormalities, lymphopenia, TPMT genetic mutation, infection)
Millennium Pharmaceuticals, Inc. Clinical Study Protocol C13007
MLN0002 EudraCT Number: 2008-002783-33 26 June 2008
Confidential 42
* TNF* antagonists
o Signs and symptoms of persistently active disease despite a history of at
least one 4 week induction regimen of one of the following agents
* Infliximab: 5 mg/kg IV, 2 doses at least 2 weeks apart
* Adalimumab: one 80 mg SC dose followed by one 40 mg dose at
least 2 weeks apart
* Certolizumab pegol: 400 mg SC, 2 doses at least 2 weeks apart OR
o Recurrence of symptoms during scheduled maintenance dosing following
prior clinical benefit (discontinuation despite clinical benefit does not
qualify) OR
o History of intolerance of at least one TNF antagonist (including, but not
limited to infusion-related reaction, demyelination, congestive heart
failure, infection)
10. May be receiving a therapeutic dose of the following drugs:
a. Oral 5-ASA compounds provided that the dose has been stable for the
2 weeks immediately prior to enrollment
b. Oral corticosteroid therapy (prednisone at a stable dose *30 mg/day,
budesonide at a stable dose *9 mg/day, or equivalent steroid) provided that
the dose has been stable for the 4 weeks immediately prior to enrollment if
corticosteroids have just been initiated, or for the 2 weeks immediately prior
to enrollment if corticosteroids are being tapered
c. Probiotics (eg, Culturelle, Saccharomyces boulardii) provided that the dose
has been stable for the 2 weeks immediately prior to enrollment
d. Antidiarrheals (eg, loperamide, diphenoxylate with atropine) for control of
chronic diarrhea
e. Azathioprine or 6-mercaptopurine provided that the dose has been stable for
the 8 weeks immediately prior to enrollment
f. Methotrexate provided that the dose has been stable for the 8 weeks
immediately prior to enrollment
g. Antibiotics used for the treatment of CD (ie, ciprofloxacin, metronidazole)
provided that the dose has been stable for the 2 weeks immediately prior to
enrollment

Exclusion Criteria
The exclusion criteria are divided into 3 categories: gastrointestinal exclusion criteria,
infectious disease exclusion criteria, and general exclusion criteria. Patients meeting any of
the following exclusion criteria are not to be enrolled in the study.
5.2.1 Gastrointestinal Exclusion Criteria
1. Evidence of abdominal abscess at the initial screening visit
2. Extensive colonic resection, subtotal or total colectomy
3. History of >3 small bowel resections or diagnosis of short bowel syndrome
4. Have received tube feeding, defined formula diets, or parenteral alimentation
within 21 days prior to the administration of the first dose of study drug
5. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine
6. Within 30 days prior to enrollment, have received any of the following for the
treatment of underlying disease:
a. Non-biologic therapies (eg, cyclosporine, thalidomide) other than those
permitted in Section 6.2
b. A non-biologic investigational therapy
c. An approved non-biologic therapy in an investigational protocol
7. Within 90 days prior to enrollment, have received any of the following:
a. Infliximab, adalimumab, or certolizumab pegol
b. Other investigational or approved biological agent
8. Any prior exposure to natalizumab or rituximab
9. Use of topical (rectal) treatment with 5-ASA or corticosteroid
enemas/suppositories within 2 weeks of the administration of the first dose of
study drug
10. Evidence of or treatment for C. difficile infection within 60 days or other intestinal
pathogen within 30 days prior to enrollment
11. Currently require or are anticipated to require surgical intervention for CD during
the study
12. History or evidence of adenomatous colonic polyps that have not been removed
Millennium Pharmaceuticals, Inc. Clinical Study Protocol C13007
MLN0002 EudraCT Number: 2008-002783-33 26 June 2008
Confidential 44
13. History or evidence of colonic mucosal dysplasia
14. Diagnosis of ulcerative colitis or indeterminate colitis
5.2.2 Infectious Disease Exclusion Criteria
1. Chronic hepatitis B or C infection
2. Active or latent tuberculosis, regardless of treatment history, as evidenced by any
of the following:
a. History of tuberculosis
b. A positive diagnostic tuberculosis (TB) test within one month of
enrollment defined as:
i. a positive QuantiFERON® test or 2 successive indeterminate
QuantiFERON® tests OR
ii. a tuberculin skin test reaction *10 mm ( *5 mm in patients receiving
the equivalent of > 15 mg/day prednisone).
c. Chest X-ray within 3 months of enrollment in which active or latent
pulmonary tuberculosis cannot be excluded
3. Any identified congenital or acquired immunodeficiency (eg, common variable
immunodeficiency, human immunodeficiency virus [HIV] infection, organ
transplantation)
4. Any live vaccinations within 30 days prior to study drug administration except for
the influenza vaccine
5. Clinically significant extra-intestinal infection (eg, pneumonia, pyelonephritis)
within 30 days of the initial screening visit
5.2.3 General Exclusion Criteria
1. Previous exposure to MLN0002
2. Female patients who are lactating or have a positive serum pregnancy test during
the screening period or a positive urine pregnancy test on Day 1 prior to study
drug administration.
3. Any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal,
gastrointestinal, genitourinary, hematological, coagulation, immunological,
Millennium Pharmaceuticals, Inc. Clinical Study Protocol C13007
MLN0002 EudraCT Number: 2008-002783-33 26 June 2008
Confidential 45
endocrine/metabolic, or other medical disorder that, in the opinion of the
investigator, would confound the study results or compromise patient safety
4. Had any surgical procedure requiring general anesthesia within 30 prior to
enrollment or is planning to undergo major surgery during the study period
5. Any history of malignancy, except for the following: (a) adequately-treated nonmetastatic
basal cell skin cancer; (b) any other type of non-melanoma skin cancer
that has been adequately treated and has not recurred for at least 1 year prior to
enrollment; and (c) adequately treated in situ cervical cancer that has not recurred
for at least 1 year prior to enrollment
6. History of any major neurological disorders, including stroke, multiple sclerosis,
brain tumor, or neurodegenerative disease
7. Positive PML subjective symptom checklist prior to the administration of the first
dose of study drug
8. Any of the following laboratory abnormalities during the screening period:
a. Hemoglobin level <8 g/dL
b. WBC count <3 × 109/L
c. Lymphocyte count <0.5 × 109/L
d. Platelet count <100 × 109/L or >1200 × 109/L
e. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
>3 × the upper limit of normal (ULN)
f. Alkaline phosphatase >3 × ULN
g. Serum creatinine >2 × ULN
9. Current or recent history (within one year prior to enrollment) of alcohol
dependence or illicit drug use
10. Active psychiatric problems that, in the investigator*s opinion, may interfere with
compliance with the study procedures
11. Unable to attend all the study visits or comply with study procedures